NASDAQ OMX

Surge in Management Liability Claims Driven by Harassment Highlights Latest Clements Worldwide Risk Index Findings

Dela

NGOs and international schools are the leading industries experiencing loss from this growing trend

 

Washington, DC, April 19, 2018 (GLOBE NEWSWIRE) -- The rise of professional and management liability due to global harassment and abuse claims is a leading cause of loss and risk among global organizations, according to the 2018 Clements Worldwide Risk Index, released today in Lagos, Nigeria in an event held in collaboration with the U.S. Embassy in Nigeria.

The survey, which is released annually, found that 17 percent of the organizations surveyed shared they were subject to a lawsuit or litigation within the last six months, with industries such as international schools (28 percent), government agencies (25 percent) and government contractors (29 percent) the most impacted by this loss.  Twenty-seven percent of NGOs and UN agencies reported that they had suffered a significant loss from professional and management liability. 

The focus on professional and management liability risks, which also includes gender pay gap and duty of care, by NGOs and international schools are new to the top featured losses and concerns of the survey, and threaten the quality of education and services provided to students and beneficiaries of their care. This coupled with emerging threats such as natural disasters, which cost the world $306 billion according to Swiss Re, nearly double the cost of 2016, and legislation posing greater challenges to program and school operations, data protection and infrastructure, make life challenging for these industries.

"Having worked in this business for over 30 years, I thought that nothing surprises me anymore, but we did not anticipate seeing such a surge in management liability claims and for it to be such a huge loss for our primary two segments - NGOs and international schools," said Dan Tuman, President, Clements Worldwide. "In today's social climate, these trends make a clear case for organizations and industries everywhere to take steps to adapt their policies accordingly and prepare for the unexpected as no one is immune to risk."

And while respondents have shifted their attention to other losses besides political violence, more than 35 percent of respondents still express worry over increased threats of political violence and disruptions from elections or political environment, up from 27 percent last year. More conflict seems likely given the existing civil wars in Syria and Yemen, Al Shabaab in East Africa and Al Qaeda in West Africa.

Furthermore, political violence and disruption may present challenges leading up to some of the important elections on the schedule this year, including the Pakistani general election, Mexican presidential election and South Sudan general election this summer; and the Thailand general election, The Democratic Republic of Congo election and United States midterm elections later this year.

Among other results reported, almost a third of respondents said that a disruption due to terrorism is likely to happen in the next six to 12 months, with 58 percent of government agencies reporting terrorism as a significant concern.

Additionally, legislation and regulatory risk remains a primary concern with nearly 37 percent believing there will be an increase in bureaucracy for business processes and specific industries like NGOs and UN organizations sharing that nearly one in four had experienced high losses from changes in regulation.

These facts reinforce that last year's global legislation and political leadership worries surrounding the rise of nationalism, trade barriers and fluctuating currencies have been replaced this year with the United States increasing tariffs on steel and aluminum, greater deregulation and protectionism by President Trump, Brexit and renewed fallout from elections; and it may get worse before it gets better.

However, the culmination of these critical risks has not deterred an overwhelming majority of respondents surveyed from expanding their international operations, with only 13 percent saying they would delay, down from 37 percent last year, which reinforces that organizations are taking the shifting geopolitical risks seriously and adapting accordingly.

The survey reports responses from more than 500 senior risk management executives in the international education, IT, manufacturing, construction, government, banking, transportation, non-government organizations (NGO), tourism, education and oil and gas sectors. In addition to today's Lagos, Nigeria event, the survey will be featured at a panel discussion next week in Amman, Jordan.

The full 2018 Clements Worldwide Risk Index, which was conducted online from January to February 2018, is now available at clements.com/riskindex.

Clements Worldwide is a leading insurance provider for expatriates and international organizations. Founded in 1947, Clements offers international car, property, term life, disability, health, specialty, and high-risk insurance in over 170 countries. With offices in Washington, D.C., London, and Dubai, Clements delivers comprehensive and customized coverage, superior customer service, and unparalleled claims response. For more information on the Clements Worldwide Risk Index and the methodology associated with the survey visit www.clements.com/riskindex. To learn more or receive a quote online, visit  www.clements.com .



Attachment

Patricia Loria
Clements Worldwide
2028720060
ploria@clements.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Clements Worldwide via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum